Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor
With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies’ results and how they’re being received by investors. Today, we’re offering insight into the latest numbers from Neurocrine Biosciences, Alnylam Pharmaceuticals and …